Skip to main content
. 2014 Aug 29;20(6):492–497. doi: 10.5152/dir.2014.14134

Table 1.

Studies published on HIFU in prostate cancer

Study Year No. of patients Guidance Notes
Boutier et al. (14) 2011 99 US Post-HIFU residual cancer in 36.4%.
Of these, 41.7% were apical lesions.
Ganzer et al. (15) 2013 538 US Actuarial BDFS (2 ng/mL):

  • 81%, 5 years

  • 61%, 10 years
Lee et al. (7) 2006 58 US BDFS at 14 months:
(3 patients with PSAs over 1.0 ng/mL):

  • Low-risk: 85%

  • Mid-risk: 77%

  • High-risk: 44%
Uchida et al. (16) 2012 884 MRI 10-year BDFS (2 ng/mL):

  • Low-risk: 71%

  • Mid-risk: 58%

  • Low-risk: 44%
Ahmed et al. (5) 2012 42 MRI No histological evidence of prostate cancer at six months in 30 of 39 patients. After re-treatment in 4 men, 39 of 41 had no evidence on mpMRI.

US, ultrasonography; HIFU, high intensity focused ultrasound; BDFS, biochemical disease-free survival; PSA, prostate specific antigen; MRI, magnetic resonance imaging; mpMRI, multiparametric magnetic resonance imaging.